Huntington's disease (HD) is a neurodegenerative disorder characterized by massive loss of medium spiny neurons in the striatum. However, the mechanisms by which mutant huntingtin leads to this selective neuronal death remain incompletely understood. Brain-derived neurotrophic factor (BDNF) has been shown to be neuroprotective on HD striatal neurons both in vitro and in vivo. ProBDNF, the precursor of mature BDNF (mBDNF), also can be secreted but promotes apoptosis of neurons expressing p75 NTR and sortilin receptors. Although a reduction of total striatal BDNF protein has been reported in HD patients and mouse models, it remains unclear whether conversion of proBDNF to mBDNF is altered in HD, and whether the proBDNF receptors, p75 NTR and sortilin are dysregulated, leading to impaired striatal neuron survival. To test these hypotheses, we generated bdnf-HA knock-in (KI) mice on the zQ175 HD background to accurately quantitate the levels of both proBDNF and mBDNF in the HD striatum. In aged zQ175 HD mice, we observed a significant loss of mBDNF and decreased TrkB activation, but no increase of proBDNF or p75 NTR levels either in the sensorimotor cortex or the striatum.
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However, immunoreactivities of p75 NTR and sortilin receptor are both increased in immature striatal oligodendrocytes, which associate with significant myelin defects in the HD striatum. Taken together, the present study indicates that diminished mature BDNF trophic signaling through the TrkB receptor, rather than an induction in proBDNF, is a main contributing factor to the vulnerability of striatal neurons in the zQ175 HD mouse model. © 2015 Elsevier Inc. All rights reserved.
Introduction
Huntington's disease (HD) is an autosomal dominant disorder associated with progressive neuronal degeneration, especially involving the caudate nucleus and putamen of the basal ganglia and the cortex (Shoulson and Chase, 1975) . The behavioral symptoms of HD include a triad of motor dysfunction, psychiatric disturbances and cognitive deficits, as well as peripheral phenotypes that include weight loss and muscle wasting (Walker, 2007) . The disease usually manifests in midlife, and is fatal after 10-15 years from the onset of symptoms (Cattaneo et al., 2005; Crook and Housman, 2011 ). An expansion of CAG trinucleotide repeats (N 35 repeats) in exon I of the interesting transcript 15 (IT15) gene has been identified as the genetic mutation responsible for the disease, which results in an elongated stretch of glutamine in the N-terminal of the huntingtin protein (HDCRG, 1993) . However, the underlying mechanisms by which mutant huntingtin leads to selective and progressive neuronal degeneration remain incompletely understood.
Brain-derived neurotrophic factor (BDNF) has been shown to have protective effects on striatal neurons both in vitro (Saudou et al., 1998) and in vivo (Bemelmans et al., 1999; Kells et al., 2004 Kells et al., , 2008 Giampa et al., 2013) . A decrease in BDNF levels in the cortex and the striatum has been reported in HD patients (Ferrer et al., 2000; Zuccato et al., 2001 Zuccato et al., , 2008 and some HD animal models (Supplemental Table 1 ). Selective deletion of BDNF in the mouse forebrain leads to loss of striatal neurons and HD-like behavioral phenotypes (Baquet et al., 2004) , and these mice exhibit changes in gene expression that are similar to the ones observed in the human HD caudate (Strand et al., 2007) . Importantly, BDNF haploinsufficiency results in earlier onset and more severe motor dysfunction in HD transgenic mice (Canals et al., 2004) , while BDNF overexpression ameliorates the symptoms of HD in mouse models (Gharami et al., 2008; Xie et al., 2010) . Thus, neurotrophic support from BDNF is a key modulator of disease progression in HD.
The vast majority (~95%) of striatal BDNF is anterogradely transported from the cortex (Altar et al., 1997; Baquet et al., 2004) . Current hypotheses underlying reduced levels of striatal BDNF observed in HD patients and animal models include loss of cortical bdnf gene transcription (Zuccato et al., 2001 (Zuccato et al., , 2003 Conforti et al., 2013) and impaired axonal transport of BDNF protein in cortical Neurobiology of Disease 82 (2015) [466] [467] [468] [469] [470] [471] [472] [473] [474] [475] [476] [477] 
